by Ethan Perlstein | Nov 24, 2016 | Perlara science |
Two weeks ago we posted Perlara’s first preprint to bioRxiv, along with all the raw data on GitHub: Predicting the phenotype of Mendelian disease missense mutations using amino acid conservation and … https://t.co/PWBuYakkMI #bioRxiv — bioRxiv...
by Feba Sam | Oct 29, 2016 | Perlara science |
High throughput screening (HTS) is essential in the process of finding a potential drug candidate, and automation is key for a good screen both in terms of robustness and efficiency. I kept hearing about the Echo since the day I joined Perlara, but it was only until a...
by Sangeetha Iyer | Sep 7, 2016 | Perlara science |
We’ve not had a worm post in awhile, but that doesn’t mean that worms (and we) haven’t been busy. We’ve been optimizing and conducting a secondary assay on them to determine if the npc disease pathology can be resolved by testing the hits that...
by Ethan Perlstein | Nov 15, 2015 | Perlara science |
PERL101 is one of our lead compounds for Niemann-Pick C. We discovered it in a whole animal screen for small molecules that suppress the delayed onset of adulthood in NPC mutant nematode larvae. The path from primary screening hit to mouse validation studies usually...
by Ethan Perlstein | Nov 4, 2015 | Perlara science |
Summary Perlstein Lab PBC (PLab) is Delaware public benefit corporation accelerating drug discovery for the 5,000+ rare genetic diseases. PLab uses a platform of CRISPR-engineered animals (yeast, nematodes, fruit flies and zebrafish) in phenotypic screens to identify...
